Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study

OBJECTIVE: To identify a suitable dosing regimen of the CD22-targeted monoclonal antibody epratuzumab in adults with moderately to severely active systemic lupus erythematosus (SLE). METHODS: A phase IIb, multicentre, randomised controlled study (NCT00624351) was conducted with 227 patients (37–39 p...

Descripción completa

Detalles Bibliográficos
Autores principales: Wallace, Daniel J, Kalunian, Kenneth, Petri, Michelle A, Strand, Vibeke, Houssiau, Frederic A, Pike, Marilyn, Kilgallen, Brian, Bongardt, Sabine, Barry, Anna, Kelley, Lexy, Gordon, Caroline
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2014
Materias:
Clinical and Epidemiological Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3888603/
https://www.ncbi.nlm.nih.gov/pubmed/23313811
http://dx.doi.org/10.1136/annrheumdis-2012-202760

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3888603/
https://www.ncbi.nlm.nih.gov/pubmed/23313811
http://dx.doi.org/10.1136/annrheumdis-2012-202760

Ejemplares similares